Clinical Trial

BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.

Study acronym: BLOOD-dose
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
BLOOD-dose is a multicentre, adaptive, randomized, multidomain platform trial designed to optimize treatment dosing strategies in adult patients with haematological diseases. The BLOOD-dose core protocol outlines the overall clinical trial design that applies to all included interventions, while domain-specific appendices (DSA) detail the unique characteristics of each domain and specify domain-specific interventions. New domains will be incorporated over time to address distinct dose-optimization research questions across different haematological conditions and interventions.
Trial Details
NCT Number NCT07474961
Lead Sponsor Anne Louise Tølbøll Sørensen
Conditions Waldenstrom Macroglobulinaemia, Multiple Myeloma
Enrollment 400 participants
Start Date 2027-03
Primary Completion 2036-12 (estimated)
Study Completion 2036-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-16